Avadel Pharmaceuticals plc (NASDAQ: AVDL) on Monday, soared 6.12% from the previous trading day, before settling in for the closing price of $8.33. Within the past 52 weeks, AVDL’s price has moved between $7.39 and $19.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 68.50%. The company achieved an average annual earnings per share of 121.57%. With a float of $88.27 million, this company’s outstanding shares have now reached $96.52 million.
Considering the fact that the conglomerate employs 188 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 90.97%, operating margin of -25.07%, and the pretax margin is -29.02%.
Avadel Pharmaceuticals plc (AVDL) Insider Activity
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Avadel Pharmaceuticals plc is 8.65%, while institutional ownership is 79.77%. The most recent insider transaction that took place on Jan 21 ’25, was worth 39,640. In this transaction Director of this company bought 5,000 shares at a rate of $7.93, taking the stock ownership to the 67,900 shares. Before that another transaction happened on Jan 13 ’25, when Company’s Director bought 10,000 for $8.04, making the entire transaction worth $80,450. This insider now owns 104,055 shares in total.
Avadel Pharmaceuticals plc (AVDL) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 121.57% per share during the next fiscal year.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) Trading Performance Indicators
Avadel Pharmaceuticals plc (AVDL) is currently performing well based on its current performance indicators. A quick ratio of 2.33 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.52, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach 0.65 in one year’s time.
Technical Analysis of Avadel Pharmaceuticals plc (AVDL)
Compared to the last year’s volume of 1.53 million, its volume of 0.93 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 91.74%. Additionally, its Average True Range was 0.43.
During the past 100 days, Avadel Pharmaceuticals plc’s (AVDL) raw stochastic average was set at 15.64%, which indicates a significant decrease from 93.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.73% in the past 14 days, which was lower than the 83.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.38, while its 200-day Moving Average is $12.53. Nevertheless, the first resistance level for the watch stands at $9.10 in the near term. At $9.36, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.79. If the price goes on to break the first support level at $8.41, it is likely to go to the next support level at $7.98. Should the price break the second support level, the third support level stands at $7.72.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) Key Stats
Market capitalization of the company is 854.21 million based on 96,629K outstanding shares. Right now, sales total 169,120 K and income totals -48,830 K. The company made 50,410 K in profit during its latest quarter, and -5,040 K in sales during its previous quarter.
